Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Xilio Therapeutics received $35.8 million in gross proceeds from Series B warrant exercises by major investors including Gilead Sciences, extending cash runway into Q2 2027. - The company achieved a development milestone for its masked antibody program under the AbbVie collaboration and nominated a development candidate for its CLDN18.2-targeting T cell engager program. - Xilio plans to submit an IND application for XTX501 in mid-2026 and advance multiple masked T cell engager programs into clinical development by 2027. - Sara Bonstein was appointed as chair of the board of directors, bringing over two decades of biotechnology executive leadership experience.
- City of Hope researchers will showcase innovative cancer treatments at the 2025 ASCO Annual Meeting, including promising data on safely readministering trastuzumab-deruxtecan to breast cancer patients after lung complications. - A precision medicine study identified specific genomic biomarkers in kidney cancer patients that predict better outcomes with adjuvant atezolizumab, potentially enabling more personalized treatment approaches. - Novel combination therapy using checkpoint inhibitors Vilastobart and atezolizumab showed tumor shrinkage in colorectal cancer patients previously unresponsive to immunotherapy, representing a significant breakthrough.
- Enara Bio has appointed Stacey Davis as Chief Business Officer and Chief Financial Officer, bringing over 25 years of biotech experience to strengthen the company's business development and capital strategy. - Clive Wood, Ph.D., former Global Head of Discovery Research at Boehringer Ingelheim and discoverer of the PD-1: PD-L1/PD-L2 pathway, joins Enara's board as Non-executive Director. - The leadership appointments come as Enara prepares to transition its lead Dark Antigen-targeted T-cell engager assets toward clinical development. - The company's EDAPT platform enables discovery of cancer-specific antigens from previously uncharted genomic 'dark matter' for developing TCR-based immunotherapies against solid tumors.
- Xilio Therapeutics reports a 27% preliminary response rate in heavily pre-treated MSS CRC patients without liver metastases using vilastobart and atezolizumab. - The combination therapy led to decreases in tumor biomarkers like CEA and ctDNA, along with improvements in clinical symptoms. - Vilastobart, a tumor-activated anti-CTLA-4, shows a differentiated safety profile with a low incidence of immune-related adverse events. - Xilio plans to present updated Phase 2 data later in 2025 and explore partnership opportunities to expand development beyond MSS CRC.
• Xilio Therapeutics has appointed Caroline Hensley as Chief Legal Officer, granting her stock options for 375,000 shares as part of her employment package. • The clinical-stage biotechnology company is developing novel tumor-activated immuno-oncology therapies designed to minimize systemic side effects while maintaining anti-tumor efficacy. • Xilio's proprietary platform focuses on creating localized anti-tumor activity within the tumor microenvironment through various modalities including cytokines, antibodies, bispecifics, and immune cell engagers.
• Xilio Therapeutics announced encouraging initial Phase 1C data for vilastobart combined with atezolizumab in advanced solid tumors. • The combination demonstrated anti-tumor activity, including unconfirmed partial responses in patients with 'cold' tumors like MSS CRC. • A patient with MSS CRC and a metastatic liver lesion showed complete resolution of the liver lesion with the vilastobart combination. • The combination was generally well-tolerated, supporting vilastobart's potential as a next-generation anti-CTLA-4 therapy.
• Xilio Therapeutics announced encouraging Phase 1 data for vilastobart (XTX101) combined with atezolizumab in advanced solid tumors. • The combination demonstrated anti-tumor activity in traditionally immunotherapy-resistant tumors, including microsatellite stable colorectal cancer (MSS CRC). • A patient with MSS CRC and a metastatic liver lesion achieved complete resolution of the liver lesion, indicating potential efficacy. • The combination was generally well-tolerated, supporting vilastobart's potential as a next-generation anti-CTLA-4 therapy.
• Xilio Therapeutics plans to initiate a Phase 2 trial of XTX101, its tumor-activated anti-CTLA-4 therapy, in combination with atezolizumab for microsatellite stable colorectal cancer in Q3 2024, with initial data expected by year-end. • The company has secured a significant partnership with Gilead Sciences for its tumor-activated IL-12 program (XTX301), receiving $43.5 million upfront and potential for up to $592.5 million in additional payments. • Following strategic portfolio prioritization, Xilio is focusing resources on advancing XTX101 and XTX301 clinical programs while developing novel tumor-activated bispecifics and immune cell engagers.
